Compare Citius Pharmaceuticals Inc (CTXR) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $241.38 (market cap $44.01B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 3006.1× Citius Pharmaceuticals Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TTWO | |
|---|---|---|
Market Cap | $14.64M | $44.01B |
Sector | Health | Media |
52-Week High | $1.82 | $262.29 |
52-Week Low | $0.53 | $189.69 |
Enterprise Value | $10.86M | $44.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Take-Two Interactive (TTWO) trades at $244.10, up 0.37% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The stock has consistently beaten earnings expectations in recent quarters, though it reported a net loss of -$4.48 billion in FY2025. Sentiment is highly positive due to strong pre-orders for Grand Theft Auto VI, priced at $79.99 with a November 2026 launch, driving analyst optimism.
The outlook is driven by GTA VI's monetization potential, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, negative profitability, and execution challenges. Institutional confidence remains strong with 79% buy ratings, but investors should monitor cash flow trends and competitive pressures in the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
